Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of tafasitamab in patients with hematologic malignancies previously treated in tafasitamab parent studies
MOH_2026-08-27_017012Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Incyte. Primary endpoint: Safety. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2026-08-27_017012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-27_017012.